Expression of MicroRNA-141 in Peripheral Blood Mononuclear Cells from Non-small-cell Lung Cancer Patients
Abstract
MicroRNAs (miRs) play a crucial role in the pathogenesis, progression, and prognosis of cancer, including non-small-cell lung cancer. The purpose of this present study was to investigate the correlation between MIR141 expression in peripheral blood mononuclear cells and serum levels of interleukins (IL-6 and IL-8) and CXCL10 in non-small-cell lung cancer patients.
Forty-six patients diagnosed with primary non-small-cell lung cancer and 30 age- and gender-matched healthy controls were recruited in this prospective cohort study. Two 3-mL samples of systemic blood were collected into tubes either containing or without an anticoagulant from all patients before treatment and from healthy controls. PBMCs were isolated, total RNA extracted, and microRNA expression measured using real-time quantitative polymerase chain reaction. Serum cytokine levels were measured by enzyme-linked immunosorbent assay.
MIR141 expression in peripheral blood mononuclear cells was significantly higher in non-small-cell lung cancer patients (4.124 [3.259–4.944]) compared to healthy controls (2.181 [1.036–2.946]). The area under the Receiver operating characteristic (ROC) curve, AUC for MIR141, was 0.695 (95% CI, 0.603–0.787), indicating statistically significant diagnostic performance. Serum levels of IL-6, IL-8, and CXCL10 were also markedly elevated in non-small-cell lung cancer patients compared to healthy controls.
Increased expression of MIR141 in peripheral blood mononuclear cells is associated with non-small-cell lung cancer and elevated systemic inflammatory mediators. These findings suggest that peripheral blood MIR141 may serve as a promising non-invasive biomarker for the diagnosis of non-small-cell lung cancer.
2. Amini M, Rezaei M, Sharifzadeh M, Hosseini S, Khorshidi A, Taheri M, et al. In vitro antiproliferative activity of cold atmospheric plasma on small-cell lung carcinoma. Biomed Biotechnol Res J. 2020;4(1):76-80.
3. Zhang Y, Chen W, Li X, Wang H, Zhou Y, Liu J, et al. Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. Lancet Oncol. 2023;24(11):1206-18.
4. Werner RS, Opitz I. Patient selection for local aggressive treatment in oligometastatic non-small cell lung cancer. Cancers (Basel). 2021;13(24):6374.
5. Chauhan A, Kalra S. Erb-b2 receptor tyrosine kinase 2 interaction with growth factor receptor-bound protein 7 acts as a molecular switch to activate non-small cell lung cancer: an in silico prediction. Biomed Biotechnol Res J. 2023;7(1):111-7.
6. Zamzam YA, Ahmed S, Hassan M, El-Sayed N, Farouk O, Abdelaziz R, et al. Promising utility of P21-activated kinase 4 expression in the prediction of recurrence in patients with early-stage non-small cell lung cancer. Biomed Biotechnol Res J. 2025;9(1):87-92.
7. Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623-40.
8. Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921-5.
9. Liu Y, Chen Q, Zhang L, Wang J, Li H, Zhou M, et al. Non-coding RNAs in lung cancer: molecular mechanisms and clinical applications. Front Oncol. 2023;13:1256537.
10. Paul S, Kumar A, Singh R, Sharma P, Verma S, Gupta N, et al. Impact of smoking-induced dysregulated human miRNAs in chronic disease development and their potential use in prognostic and therapeutic purposes. J Biochem Mol Toxicol. 2022;36(9):e23134.
11. Doghish AS, Elshafiee ES, Kamel MM, Salama MM, Ibrahim MM, et al. A study of miRNAs as cornerstone in lung cancer pathogenesis and therapeutic resistance: a focus on signaling pathways interplay. Pathol Res Pract. 2022;238:154053.
12. Dezfuli NK, Abedi A, Jafari N, Rahimi S, Khodadadi I, et al. Evaluation expression of miR-146a and miR-155 in non-small-cell lung cancer patients. Front Oncol. 2021;11:4356.
13. Cavallari I, Sahnane N, Bonomi M, Bria E, Bersani I, et al. The miR-200 family of microRNAs: fine tuners of epithelial-mesenchymal transition and circulating cancer biomarkers. Cancers (Basel). 2021;13(23):5874.
14. Sundararajan V, Burk UC, Bajdak-Rusinek K. Revisiting the miR-200 family: a clan of five siblings with essential roles in development and disease. Biomolecules. 2022;12(6):781.
15. Dabous E, Guirgis A, Khalil H. Targeting tumor suppressor genes by miR-141 family as a potential regulatory function in cervical cancer. J Intern Med Sci Art. 2023;4:47-53.
16. Li Y, Gu F, Lin X. The role of miR-141/Sirt1 in colon cancer. J BUON. 2020;25(6):2665-71.
17. Luo QQ, Zhang P, Li J, Chen Y, Wang Y, et al. Functional mechanism and clinical implications of miR-141 in human cancers. Cell Signal. 2022;95:110354.
18. Mao Y, Li W, Zhang Q, Chen H, Zhou J, et al. Mechanisms and functions of miR-200 family in hepatocellular carcinoma. Onco Targets Ther. 2021;14:13479-90.
19. Richardsen E, Uglehus RD, Due EU, Andersen S, Busund LR, et al. MicroRNA 141 is associated to outcome and aggressive tumor characteristics in prostate cancer. Sci Rep. 2019;9(1):386.
20. Kong YJ, Zhang Y, Liu X, Wang X, Li F, et al. miR-141 promotes cell proliferation and invasion in non-small cell lung cancer by targeting KLF9. Eur Rev Med Pharmacol Sci. 2019;23(23):10415-22.
21. Smolle E, Pichler M, Pichler R, et al. Liquid biopsy in non-small cell lung cancer—current status and future outlook—a narrative review. Transl Lung Cancer Res. 2021;10(5):2237-52.
22. Yang G, Li X, Chen H, Zhang L, Zhao X, et al. Circulating miR-141 as a potential biomarker for diagnosis, prognosis and therapeutic targets in gallbladder cancer. Sci Rep. 2022;12(1):10072.
23. Mao S, Li X, Chen Y, Zhang Q, et al. Exosomal miR-141 promotes tumor angiogenesis via KLF12 in small cell lung cancer. J Exp Clin Cancer Res. 2020;39:1-16.
24. Guz M, Jeleniewicz W, Cybulski M, et al. Interactions between circRNAs and miR-141 in cancer: from pathogenesis to diagnosis and therapy. Int J Mol Sci. 2023;24(14):11861.
25. Ma Z, Li Y, Chen L, Wang J, Zhang X, et al. RHOJ induces epithelial-to-mesenchymal transition by IL-6/STAT3 to promote invasion and metastasis in gastric cancer. Int J Biol Sci. 2023;19(14):4411-28.
26. Deng F, Zhang Y, Li H, Wang X, et al. Overexpression of IL-8 promotes cell migration via PI3K-Akt signaling pathway and EMT in triple-negative breast cancer. Pathol Res Pract. 2020;216(4):152902.
27. Guo J, Zhang H, Li Z, Chen Y, Wang L, et al. Empowering therapeutic antibodies with IFN-α for cancer immunotherapy. PLoS One. 2019;14(8):e0219829.
28. Awad AM, Mohamed EA, Hassan HA, El-Sayed R, et al. MicroRNA-141-regulated KLK10 and TNFSF-15 gene expression in hepatoblastoma cells as a novel mechanism in liver carcinogenesis. Sci Rep. 2024;14(1):13492.
29. Masyeni S, Yusuf I, Arifin H, et al. Correlation of miR-150, hsa-let-7e, and miR-146a and gene expression of IL-6, IL-8, IP-10, and MIP-1β during dengue virus infection. Narra J. 2021;1(1):e31.
30. Nagasaka M, Toyokawa G, Okamoto T, et al. Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer. Mol Cancer. 2021;20:1-16.
31. Raycheva GA, Ivanov HY, Grudeva-Popova ZG. Liquid biopsy–possibilities for monitoring the therapeutic response in non-small cell lung cancer. Folia Med (Plovdiv). 2021;63(6):839-46.
32. Chen K, Li H, Zhang X, Wang Y, et al. Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer. Cancer Cell. 2023;41(10):1749-62.e6.
| Files | ||
| Issue | Articles in Press | |
| Section | Original Article(s) | |
| Keywords | ||
| Cytokines Immune system MIR141 Non-small-cell lung carcinoma | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
